The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification
Abstract
Purpose: To improve the risk stratification of patients with rhabdomyosarcoma (RMS) through the use of clinical and molecular biologic data. Patients and Methods: Two independent data sets of gene-expression profiling for 124 and 101 patients with RMS were used to derive prognostic gene signatures by using a meta-analysis. These and a previously published metagene signature were evaluated by using cross validation analyses. A combined clinical and molecular risk-stratification scheme that incorporated the PAX3/FOXO1 fusion gene status was derived from 287 patients with RMS and evaluated. Results: We showed that our prognostic gene-expression signature and the one previously published performed well with reproducible and significant effects. However, their effect was reduced when cross validated or tested in independent data and did not add new prognostic information over the fusion gene status, which is simpler to assay. Among nonmetastatic patients, patients who were PAX3/FOXO1 positive had a significantly poorer outcome compared with both alveolar-negative and PAX7/FOXO1-positive patients. Furthermore, a new clinicomolecular risk score that incorporated fusion gene status (negative and PAX3/FOXO1 and PAX7/FOXO1 positive), Intergroup Rhabdomyosarcoma Study TNM stage, and age showed a significant increase in performance over the current risk-stratification scheme. Conclusion: Gene signatures can improve current stratification of patients with RMS but will require complex assays to be developed and extensive validation before clinical application. A significant majority of their prognostic value was encapsulated by the fusion gene status. A continuous risk score derived from the combination of clinical parameters with the presence or absence of PAX3/FOXO1 represents a robust approach to improving current risk-adapted therapy for RMS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modern Applied Statistics with S
Venables, W. N., & Ripley, B. D. (2002) · Statistics and Computing · doi:10.1007/978-0-387-21706-2 · Cited by 24,305
Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & Pepe, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,854
Khan, J., Wei, J. S., Ringnér, M., Saal, L. H., Ladanyi, M., Westermann, F., Berthold, F., Schwab, M., Antonescu, C. R., Peterson, C., et al. (2001) · Nature Medicine · doi:10.1038/89044 · Cited by 2,644
Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic Disease
Crist, W. M., Anderson, J. R., Meza, J. L., Fryer, C., Raney, R. B., Ruymann, F. B., Breneman, J., Qualman, S. J., Wiener, E., Wharam, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.3091 · Cited by 1,087
Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma
Galili, N., Davis, R. J., Fredericks, W. J., Mukhopadhyay, S., Rauscher, F. J., Emanuel, B. S., Rovera, G., & Barr, F. G. (1993) · Nature Genetics · doi:10.1038/ng1193-230 · Cited by 892
Sorensen, P. H. B., Lynch, J. C., Qualman, S. J., Tirabosco, R., Lim, J. F., Maurer, H. M., Bridge, J. A., Crist, W. M., Triche, T. J., & Barr, F. G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.137 · Cited by 742
Williamson, D., Missiaglia, E., de Reyniès, A., Pierron, G., Thuille, B., Palenzuela, G., Thway, K., Orbach, D., Laé, M., Fréneaux, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3814 · Cited by 502
Self-citationOberlin, O., Rey, A., Lyden, E., Bisogno, G., Stevens, M. C. G., Meyer, W. H., Carli, M., & Anderson, J. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7207 · Cited by 484
Self-citationGene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma
Barr, F. G. (2001) · Oncogene · doi:10.1038/sj.onc.1204599 · Cited by 383
A comparison of heterogeneity variance estimators in combining results of studies
Sidik, K., & Jonkman, J. N. (2007) · Statistics in Medicine · doi:10.1002/sim.2688 · Cited by 380
Cited by
Shern, J. F., Chen, L., Chmielecki, J., Wei, J. S., Patidar, R., Rosenberg, M., Ambrogio, L., Auclair, D., Wang, J., Song, Y. K., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0639 · Cited by 756
PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability
Gryder, B. E., Yohe, M. E., Chou, H.-C., Zhang, X., Marques, J., Wachtel, M., Schaefer, B., Sen, N., Song, Y., Gualtieri, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1297 · Cited by 316
Skapek, S. X., Anderson, J., Barr, F. G., Bridge, J. A., Gastier-Foster, J. M., Parham, D. M., Rudzinski, E. R., Triche, T., & Hawkins, D. S. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24532 · Cited by 278
Tremblay, A. M., Missiaglia, E., Galli, G. G., Hettmer, S., Urcia, R., Carrara, M., Judson, R. N., Thway, K., Nadal, G., Selfe, J. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.029 · Cited by 178
Self-citationThe Hippo signal transduction network in skeletal and cardiac muscle
Wackerhage, H., Del Re, D. P., Judson, R. N., Sudol, M., & Sadoshima, J. (2014) · Science Signaling · doi:10.1126/scisignal.2005096 · Cited by 92
Metadata
- Authors
- Missiaglia, E., Williamson, D., Chisholm, J., Wirapati, P., Pierron, G., Petel, F., Concordet, J.-P., Thway, K., Oberlin, O., Pritchard-Jones, K., Delattre, O., Delorenzi, M., & Shipley, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-05-10
- Volume
- 30
- Issue
- 14
- Pages
- 1670-1677
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2103077999
- Cited by
- 365
- References
- 29
- FWCI
- 20.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification. https://app.cochat.ai/papers/10.1200/jco.2011.38.5591
- The paper
- Missiaglia, E., Williamson, D., Chisholm, J., Wirapati, P., Pierron, G., Petel, F., Concordet, J.-P., Thway, K., Oberlin, O., Pritchard-Jones, K., Delattre, O., Delorenzi, M., & Shipley, J. (2012). PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.38.5591
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.